WO2007125295A3 - Treatment of hypothyroidism - Google Patents

Treatment of hypothyroidism Download PDF

Info

Publication number
WO2007125295A3
WO2007125295A3 PCT/GB2007/001477 GB2007001477W WO2007125295A3 WO 2007125295 A3 WO2007125295 A3 WO 2007125295A3 GB 2007001477 W GB2007001477 W GB 2007001477W WO 2007125295 A3 WO2007125295 A3 WO 2007125295A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
hypothyroidism
thyroid
hypoactive
medicament
Prior art date
Application number
PCT/GB2007/001477
Other languages
French (fr)
Other versions
WO2007125295A2 (en
Inventor
Richard Ross
Original Assignee
Diurnal Ltd
Richard Ross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd, Richard Ross filed Critical Diurnal Ltd
Publication of WO2007125295A2 publication Critical patent/WO2007125295A2/en
Publication of WO2007125295A3 publication Critical patent/WO2007125295A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]

Abstract

The disclosure relates to a medicament for the treatment of thyroid disorders that typically result from a hypoactive thyroid gland.
PCT/GB2007/001477 2006-04-28 2007-04-23 Treatment of hypothyroidism WO2007125295A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0608402A GB0608402D0 (en) 2006-04-28 2006-04-28 Thyroid treatment
GB0608402.4 2006-04-28

Publications (2)

Publication Number Publication Date
WO2007125295A2 WO2007125295A2 (en) 2007-11-08
WO2007125295A3 true WO2007125295A3 (en) 2008-01-31

Family

ID=36589960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001477 WO2007125295A2 (en) 2006-04-28 2007-04-23 Treatment of hypothyroidism

Country Status (2)

Country Link
GB (1) GB0608402D0 (en)
WO (1) WO2007125295A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100136109A1 (en) * 2007-04-23 2010-06-03 Richard Ross Sustained release
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0550108A1 (en) * 1991-12-30 1993-07-07 Akzo Nobel N.V. Sustained release thyroactive composition
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
WO2001087272A2 (en) * 2000-05-18 2001-11-22 Therics, Inc. Encapsulating a toxic core within a non-toxic region in an oral dosage form

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0550108A1 (en) * 1991-12-30 1993-07-07 Akzo Nobel N.V. Sustained release thyroactive composition
WO1999043307A1 (en) * 1998-02-26 1999-09-02 Prange Arthur J Jr Thyroid hormone replacement using sustained release triiodothyronine
WO2001087272A2 (en) * 2000-05-18 2001-11-22 Therics, Inc. Encapsulating a toxic core within a non-toxic region in an oral dosage form

Also Published As

Publication number Publication date
GB0608402D0 (en) 2006-06-07
WO2007125295A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2008070268A3 (en) Pharmaceutical compositions
WO2006130399A3 (en) Therapeutic combinations and methods including irm compounds
MX2010006823A (en) Methods for the treatment of gout.
TW200736181A (en) Anti-reflective coatings
PL1993985T3 (en) Process for the preparation of 1,2-propanediol
WO2007144195A3 (en) Pharmaceutical composition with synergistic anticonvulsant effect
WO2008063849A3 (en) Multiple sclerosis therapy
EP1983972A4 (en) Compounds for the treatment of metabolic disorders
ZA200808963B (en) Compounds for the treatment of metabolic disorders
SG154441A1 (en) Treatment of demyelinating disorders
WO2007084857A3 (en) Methods and compositions for treating cell proliferative disorders
WO2007077352A3 (en) Device for redistributing the catalyst in fcc risers
PT2056814E (en) 2,5-dihydroxybenzene compounds for the treatment of psoriasis
CL2007002479A1 (en) COMPOUNDS DERIVED FROM PIRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS.
IL192852A0 (en) Compounds for the treatment of metabolic disorders
WO2010119102A3 (en) Pharmaceutical composition containing proton pump inhibitor for treating dermatological autoimmune diseases
MY149433A (en) Nutritional compositions containing punicalagins
MX2009005117A (en) Use of clostridium perfringens type c bacterium for the manufacture of a vaccine.
MX2010003591A (en) Mechanical protective layer for solid dosage forms.
WO2007125295A3 (en) Treatment of hypothyroidism
IL192851A0 (en) Compounds for the treatment of metabolic disorders
WO2008019388A3 (en) Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome
WO2008021932A3 (en) Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
SG155120A1 (en) Crimping device
WO2008129303A3 (en) Sustained release

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732516

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07732516

Country of ref document: EP

Kind code of ref document: A2